EYPT EyePoint Pharmaceuticals Inc

$EYPT Alright everyone, I am still around but not posting. Here is my latest and you know it. 1. DURAVYU is a fundamentally different treatment concept. EyePoint uses a bioerodible sustained-release insert containing vorolanib. Rather than extending the half-life of an injected antibody, the goal is to maintain continuous VEGF-pathway suppression inside the eye for roughly six months. Kodiak’s Zenkuda remains an intravitreal biologic injection whose ABC technology extends ocular exposure. That distinction could matter commercially. If DURAVYU ultimately delivers reliable six-month control, the physician is essentially placing a sustained drug depot rather than trying to determine how far an individual patient can be stretched between injections. Continued below

$EYPT If Lucia is successful, the duration is 33% longer before retreat compared to KOD. The technology and delivery system is superior, KOD is antiquated gel release not more precisely engineered dissolvable inserts. Eypt is actually superior both in terms of duration and technology. So f this. If they csn go to 100.00 so shall we. Plus we have the in house MFG facilities

$EYPT 9 outlier patients is not going to bring down this company . Duravyu is solid and I’m confident Lucia will deliver . We will be back 👊

$EYPT From Regillo’s presentation this week at Retina society. 0.5% ≥15-letter loss in the LUGANO aflibercept arm versus roughly 3–6% historically is suspiciously clean. If LUCIA somehow gets another suspiciously spotless Eylea arm, we’re going to need to meet whoever’s spinning that randomization wheel.

$EYPT Today’s Schedule G is a badly needed confirmation that mega shareholders still have confidence in EYPT and its potential for success. Cheers and glta longs.

$EYPT Kodiak, Ocular, and the broader biotech sector (XBI) had the same sell off pattern today. Not sure wtf is going on. I’m convinced lugano was a total fluke heavily influenced by that unusually favorable control arm. A difference of just two or three patients could have changed the outcome. If lucia even barely hits and the entire narrative gets rewritten. Having said that, EYPT has been really freaking quiet the past couple of weeks post EuRetina and AAO. While OCUL is swinging its dick all over social media. Will find out in a few weeks or less…

$EYPT there a few nubes on this board that don’t understand how biotech market works in relation to the MMs . SP heavily controlled . Especially on Opex week . XBI flush out just bonus points for them . At some point the SP gets run up out of nowhere . Same thing happened to Ocul post P1 DR results . MM’s move in like vultures and mass buy once peak sentiment is at absolute low and RSI beaten to death . Retail has zero control of the situation.

$EYPT Just wait until the clinical trials go well Eypt will skyrocket at least back to where it was prior to the dip 💨 🚀 🌕

$EYPT Just to reiterate in the simplest form: The primary endpoint is the headline grabber and it absolutely matters but the LUGANO story goes well beyond that “miss” DURAVYU delivered across the key secondary endpoints: a 42% reduction in treatment burden, strong supplement-free rates, strong anatomical control, and a favorable safety profile with repeat dosing. That’s why LUCIA matters so much. If LUCIA cleanly hits the primary endpoint while reproducing LUGANO’s secondary results, the overall Phase 3 package could look very different from what the LUGANO headline alone suggests.

$EYPT $EYPT The deeper LUGANO gets analyzed, the stronger the DURAVYU story looks. Different audits of the data—outlier analysis, median BCVA, supplement-free patients, anatomy, rescue response, GA and safety—all keep pointing the same direction: the headline miss looks increasingly like an anomalous statistical outcome, not a failed drug. LUCIA is still binary, but the totality of evidence makes success look more likely than not to me. At these prices, I wouldn’t want to be short. This has the feel of a phoenix rising.

$EYPT bring it down to sub 4 , my wallet is open . You are a long-term investor in this stock because you believe in the Duravyu technology and market potential. Investors that get spooked because SP impacted by XBI volatility need to toughen up . Never let a “crises” go to waste .

$EYPT This is no more a matter of profit for me i want all those shorts whobare suppressing it fucked !

$EYPT yesterday I sold 5,000 shares out of 15,000 to make some profit. If this falls to around the $3.10 mark again I will be buying the 5,000 shares I sold back and an additional 5,000 shares. I believe with this price action and looking back on charts that this has been pushed down for re entry points for insiders. I think good news is coming and they know it.

$EYPT I wonder if the "doctor" is going to pat himself on the back for today's prediction...like he did for yesterday's. Ivor

$EYPT when people post things on here like "Case closed" "end of story" in a vote of confidence....yet they are down 71% on this investment. Realize they are doing so with HOPE not facts...because the only fact here that matters is that EYPT missed it's primary endpoint.

$EYPT Above $5 on another genuinely heavy-volume day, I'd view the recovery thesis much more seriously. The biggest upcoming test remains The Retina Society meeting next week, September 23–26. A convincing LUGANO presentation combined with this emerging price/volume reversal and ~18M shares still short is the combination that could finally light the fuse. We're not at $15–$18 territory yet, but yesterday was the first price action in several checks that actually moved in the direction thesis needs

$EYPT I used EYPT today and cleared my vision for 8 dollar next week ;) Thank you for your attention !

$EYPT first bought shares .37 day of crash only to see over six dollars SP few days later….I had ten 5.00 calls for this Friday also. I got greedy thinking this would be 7-8 no time Today completely destroyed my calls for Friday and my shares are now heavy bags Humble pie tastes like crap

$EYPT Watching EYPT drift lower is frustrating, but for those who truly believe in LUCIA, it doesn’t change much. LUCIA remains a binary-risk event, and the outcome will ultimately matter far more than the short-term price action. I don’t have the financial room to add, so I’m just waiting to see how LUCIA plays out. If LUCIA fails, the money invested was at risk anyway. If it succeeds, there’s still plenty of upside. For long-term believers, the current weakness could actually be an opportunity to add at much lower prices.

$EYPT Don't cry like babies calling it scam Everyone knows biopharma stocks carry binary risk wait and watch what it will bring to us. Definitely it will go 6+ hold and wait. The way it's goes down it will rise the same way or may be faster.